A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

[1]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2014, The Cochrane database of systematic reviews.

[2]  S. Brand,et al.  Rate of Malignancies and Infections in a Large Single Center Cohort of IBD Patients Treated With Thiopurines and Anti-TNF-Antibodies , 2011 .

[3]  F. Rizzello,et al.  Cancer in Crohn's Disease patients treated with infliximab: A long‐term multicenter matched pair study , 2011, Inflammatory bowel diseases.

[4]  T. Dassopoulos,et al.  Thiopurine therapy in inflammatory bowel disease , 2010, Expert review of gastroenterology & hepatology.

[5]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[6]  I. Ferkolj.  How to improve the safety of biologic therapy in Crohn's disease. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[7]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[8]  W. Sandborn,et al.  Adalimumab safety in global clinical trials of patients with Crohn's disease , 2009, Inflammatory bowel diseases.

[9]  B. Sands,et al.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  P. Rutgeerts,et al.  Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2007, Gut.

[11]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[13]  F. Rizzello,et al.  Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study , 2005, Gut.

[14]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[15]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[16]  L. Biancone,et al.  Maintenance treatment of Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[17]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[18]  S. Targan,et al.  Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study , 2001, Inflammatory bowel diseases.

[19]  P. Rutgeerts,et al.  Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[20]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[21]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[22]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[23]  D. Hommes,et al.  Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.

[24]  J. Stockman.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2011 .

[25]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.